Sami Abu Hamdeh1, Johan Virhammar2, Dag Sehlin3, Irina Alafuzoff4, Kristina Giuliana Cesarini1, Niklas Marklund1. 1. 1Department of Neuroscience, Section of Neurosurgery, Uppsala University. 2. 2Department of Neuroscience, Neurology, Uppsala University Hospital, Uppsala University. 3. 3Department of Public Health and Caring Sciences/Geriatrics, Uppsala University; and. 4. 4Department of Pathology, Uppsala University Hospital, Uppsala University, Uppsala, Sweden.
Abstract
OBJECTIVE: The authors conducted a study to test if the cortical brain tissue levels of soluble amyloid beta (Aβ) reflect the propensity of cortical Aβ aggregate formation and may be an additional factor predicting surgical outcome following idiopathic normal pressure hydrocephalus (iNPH) treatment. METHODS: Highly selective ELISAs (enzyme-linked immunosorbent assays) were used to quantify soluble Aβ40, Aβ42, and neurotoxic Aβ oligomers/protofibrils, associated with Aβ aggregation, in cortical biopsy samples obtained in patients with iNPH (n = 20), sampled during ventriculoperitoneal (VP) shunt surgery. Patients underwent pre- and postoperative (3-month) clinical assessment with a modified iNPH scale. The preoperative CSF biomarkers and the levels of soluble and insoluble Aβ species in cortical biopsy samples were analyzed for their association with a favorable outcome following the VP shunt procedure, defined as a ≥ 5-point increase in the iNPH scale. RESULTS: The brain tissue levels of Aβ42 were negatively correlated with CSF Aβ42 (Spearman’s r = -0.53, p < 0.05). The Aβ40, Aβ42, and Aβ oligomer/protofibril levels in cortical biopsy samples were higher in patients with insoluble cortical Aβ aggregates (p < 0.05). The preoperative CSF Aβ42 levels were similar in patients responding (n = 11) and not responding (n = 9) to VP shunt treatment at 3 months postsurgery. In contrast, the presence of cortical Aβ aggregates and high brain tissue Aβ42 levels were associated with a poor outcome following VP shunt treatment (p < 0.05). CONCLUSIONS: Brain tissue measurements of soluble Aβ species are feasible. Since high Aβ42 levels in cortical biopsy samples obtained in patients with iNPH indicated a poor surgical outcome, tissue levels of Aβ species may be associated with the clinical response to shunt treatment.
OBJECTIVE: The authors conducted a study to test if the cortical brain tissue levels of soluble amyloid beta (Aβ) reflect the propensity of cortical Aβ aggregate formation and may be an additional factor predicting surgical outcome following idiopathic normal pressure hydrocephalus (iNPH) treatment. METHODS: Highly selective ELISAs (enzyme-linked immunosorbent assays) were used to quantify soluble Aβ40, Aβ42, and neurotoxic Aβ oligomers/protofibrils, associated with Aβ aggregation, in cortical biopsy samples obtained in patients with iNPH (n = 20), sampled during ventriculoperitoneal (VP) shunt surgery. Patients underwent pre- and postoperative (3-month) clinical assessment with a modified iNPH scale. The preoperative CSF biomarkers and the levels of soluble and insoluble Aβ species in cortical biopsy samples were analyzed for their association with a favorable outcome following the VP shunt procedure, defined as a ≥ 5-point increase in the iNPH scale. RESULTS: The brain tissue levels of Aβ42 were negatively correlated with CSF Aβ42 (Spearman’s r = -0.53, p < 0.05). The Aβ40, Aβ42, and Aβ oligomer/protofibril levels in cortical biopsy samples were higher in patients with insoluble cortical Aβ aggregates (p < 0.05). The preoperative CSF Aβ42 levels were similar in patients responding (n = 11) and not responding (n = 9) to VP shunt treatment at 3 months postsurgery. In contrast, the presence of cortical Aβ aggregates and high brain tissue Aβ42 levels were associated with a poor outcome following VP shunt treatment (p < 0.05). CONCLUSIONS: Brain tissue measurements of soluble Aβ species are feasible. Since high Aβ42 levels in cortical biopsy samples obtained in patients with iNPH indicated a poor surgical outcome, tissue levels of Aβ species may be associated with the clinical response to shunt treatment.
Entities:
Keywords:
AD = Alzheimer’s disease; Alzheimer’s disease; Aβ = amyloid beta; Aβ oligomers; ELISA = enzyme-linked immunosorbent assay; HPtau = hyperphosphorylated tau protein; LOD = limit of detection; LP = lumboperitoneal; MMSE = Mini-Mental State Examination; VP = ventriculoperitoneal; amyloid-β; hydrocephalus; iNPH; iNPH = idiopathic normal pressure hydrocephalus
Authors: Anna Jeppsson; Carsten Wikkelsö; Kaj Blennow; Henrik Zetterberg; Radu Constantinescu; Anne M Remes; Sanna-Kaisa Herukka; Tuomas Rauramaa; Katarina Nagga; Ville Leinonen; Mats Tullberg Journal: J Neurol Neurosurg Psychiatry Date: 2019-06-05 Impact factor: 10.154
Authors: Heikki Lukkarinen; Anna Jeppsson; Carsten Wikkelsö; Kaj Blennow; Henrik Zetterberg; Radu Constantinescu; Anne M Remes; Sanna-Kaisa Herukka; Mikko Hiltunen; Tuomas Rauramaa; Katarina Nägga; Ville Leinonen; Mats Tullberg Journal: Fluids Barriers CNS Date: 2022-02-05
Authors: Manuel Menendez-Gonzalez; Huber S Padilla-Zambrano; Gabriel Alvarez; Estibaliz Capetillo-Zarate; Cristina Tomas-Zapico; Agustin Costa Journal: Front Aging Neurosci Date: 2018-04-16 Impact factor: 5.750